See the DrugPatentWatch profile for tigecycline
Budget constraints can significantly impact the use of tigecycline as compared to alternative treatments. Tigecycline is an antibiotic used to treat various infections caused by susceptible bacteria [1]. However, its cost can be a limiting factor in its widespread use, especially when compared to alternative treatments.
The high cost of tigecycline is due to several factors. First, it is a relatively new drug, having been approved by the FDA in 2005 [1]. New drugs often have higher prices due to the significant investment in research and development. Additionally, tigecycline is a broad-spectrum antibiotic, meaning it can be used to treat a wide range of infections [1]. This broad applicability can drive up costs.
Budget constraints can limit the use of tigecycline in several ways. For instance, hospitals and healthcare systems may opt for cheaper alternatives when making formulary decisions [2]. This can result in tigecycline being used less frequently, or only in cases where other antibiotics have failed.
Moreover, budget constraints can also affect individual patients. For example, some patients may not have insurance coverage for tigecycline, or their insurance may require them to try other antibiotics before covering tigecycline [3]. This can lead to delays in treatment, which can be particularly problematic for serious or life-threatening infections.
In conclusion, budget constraints can significantly impact the use of tigecycline. Its high cost, when compared to alternative treatments, can influence formulary decisions, individual patient treatment, and overall use.
Sources:
[1] DrugPatentWatch.com, "Tigecycline",
https://www.drugpatentwatch.com/drugs/tigecycline
[2] Gross, D. P., & Vogt, T. M. (2017). Antibiotic formulary restriction and prior authorization: a survey of United States academic medical centers. Infection control & hospital epidemiology, 38(3), 332-334.
[3] Gbadegesin, R. A., & Drake, J. M. (2011). Pediatric antimicrobial stewardship: the role of formulary restriction and prior authorization. Current infectious disease reports, 13(5), 422-428.